Lumicell
MIT spin-out whose Lumisight dye and imaging system show leftover breast cancer in the lumpectomy cavity before the operation ends.
Overview
Lumicell's pegulicianine (Lumisight) and the Lumicell Direct Visualization System were approved by the FDA in April 2024 after the INSITE trial; the combination is the first optical imaging agent approved for breast cancer surgery.
Scorecard
All companies- approved products +6
- modalities +2
- regions +1
Pages like this
not linked directly; found by shared links- CompanyPerimeter Medical Imaging AI
Shares Optical & fluorescence imaging, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- CompanyNearWave
Shares Optical & fluorescence imaging, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- CompanyVergent Bioscience
Shares Optical & fluorescence imaging, Fluorescence-guided surgery.
- Product5-Aminolevulinic acid (oral, for glioma surgery)
Shares Optical & fluorescence imaging, Fluorescence-guided surgery.
- IdeaReal-time margin assessment and image-guided surgery as the global standard
Shares Optical & fluorescence imaging, Fluorescence-guided surgery, HR-positive / HER2-negative breast cancer.
- PersonDonna McKay
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonSunil Lakhani
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PersonPriya Rastogi
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.